Steward Partners Investment Advisory LLC Has $158,000 Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Steward Partners Investment Advisory LLC grew its holdings in Illumina, Inc. (NASDAQ:ILMN) by 57.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,182 shares of the life sciences company’s stock after purchasing an additional 431 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Illumina were worth $158,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Janney Montgomery Scott LLC increased its holdings in Illumina by 73.3% during the 3rd quarter. Janney Montgomery Scott LLC now owns 6,580 shares of the life sciences company’s stock worth $858,000 after purchasing an additional 2,783 shares in the last quarter. KBC Group NV increased its holdings in Illumina by 2.1% during the 3rd quarter. KBC Group NV now owns 42,516 shares of the life sciences company’s stock worth $5,544,000 after purchasing an additional 859 shares in the last quarter. Huntington National Bank increased its holdings in Illumina by 29.4% during the 3rd quarter. Huntington National Bank now owns 515 shares of the life sciences company’s stock worth $67,000 after purchasing an additional 117 shares in the last quarter. Metis Global Partners LLC increased its holdings in Illumina by 9.1% during the 3rd quarter. Metis Global Partners LLC now owns 3,575 shares of the life sciences company’s stock worth $466,000 after purchasing an additional 299 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. increased its holdings in Illumina by 7.0% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,978 shares of the life sciences company’s stock worth $649,000 after purchasing an additional 326 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Stock Up 1.8 %

NASDAQ ILMN opened at $85.60 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The stock has a market capitalization of $13.56 billion, a PE ratio of -11.15, a PEG ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a 1 year low of $80.18 and a 1 year high of $156.66. The business’s 50-day moving average is $113.52 and its 200 day moving average is $129.86.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Sell-side analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ILMN has been the topic of a number of research analyst reports. Morgan Stanley cut their target price on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 11th. Royal Bank of Canada cut their target price on Illumina from $247.00 to $128.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 12th. Barclays restated an “underweight” rating on shares of Illumina in a research note on Tuesday, March 11th. HSBC downgraded Illumina from a “buy” rating to a “hold” rating and set a $100.00 target price on the stock. in a research note on Friday, February 28th. Finally, Guggenheim cut their target price on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $140.90.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.